SLC5A2 and diabetes mellitus: When SGLT2 inhibitors were provided, the same group showed diabetes-associated increases in inflammation-suppressed NLRP3 inflammasome activity as well as lower mRNA levels of ASC, IL-6, IL-1b, TNF-a, and caspase-1.